A Study to Assess Efficacy and Safety of KarXT in Acutely Psychotic Hospitalized Adult Patients With Schizophrenia (EMERGENT-2)
Clinical trial NCT04659161 · COMPLETED
Trial details
- NCT number
- NCT04659161
- Sponsor
- Karuna Therapeutics, Inc., a Bristol Myers Squibb company
- Status
- COMPLETED
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2020-12-16
- Primary completion
- 2022-05-24
- Enrollment
- 252
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.